Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

Rifabutin Low Dose-Induced Intermediate Uveitis in a Patient with Acquired Immunodeficiency Syndrome

Agustina C. Palacio, Mercedes Cabrini, Graciela Ben, Emilio M. Dodds*

Department of Ophthalmology, Consultores Oftalmológicos, Buenos Aires, Argentina

Abstract: Intermediate uveitis is a relatively rare manifestation of Rifabutin induced uveitis. Rifabutin toxicity is unusual at doses of 300 mg daily or less. The purpose of this study is to report the case of an HIV+ patient with unilateral rifabutin induced intermediate uveitis after 4 months of treatment with low dose rifabutin (150 mg daily) in combination with ritonavir and fluconazole. The uveitis resolved after drug discontinuance and the use topical corticosteroids.

Keywords: Rifabutin, drug induced uveitis, intermediate uveitis, vitritis, drug interaction

Citation: Agustina C. Palacio, Mercedes Cabrini, Graciela Ben, Emilio M. Dodds, Rifabutin Low Dose-Induced Intermediate Uveitis in a Patient with Acquired Immunodeficiency Syndrome. American Journal of Medical Case Reports, 5 (5). 116-118. January 2017. doi:10.12691/ajmcr-5-5-3

1. Background

Rifabutin is a semi-synthetic antimycobacterial from the rifamicin family agent mainly used in the treatment of Mycobacterium avium-complex (MAC) and tuberculosis in AIDS patients. Although anterior uveitis with hypopyon is the most common presentation, numerous cases of rifabutin induced uveitis associated with various degrees of vitritis have been reported previously [1,2,3,4,5]. This side effect seems to be dose dependent and rapidly resolves after topical corticosteroid therapy and rifabutin discontinuation.

We report the case of a rifabutin-induced intermediate uveitis in an HIV+ patient with a low dose of rifabutin.

2. Case Report

A 48-year-old white man was referred to the uveitis clinic with decreased vision in his right eye. The patient reported red eye and blurry vision of 4 days of progress. His medical history was significant for HIV infection and pulmonary tuberculosis that had been treated with classic therapy for 2 months and then continued with maintenance therapy for over 4 months. For this condition, he was under highly active antiretroviral combination therapy (HAART) with tenofovir/emtricitabine/atazanavir/ritonavir. He was on isoniazid and rifabutin 150 mg/day as maintenance of the anti-tuberculosis treatment. He was also taking fluconazole 200 mg/week for onychomycosis. His past ocular history was insignificant.

His best-corrected acuity was counting fingers in the right eye and 20/20 in the left eye. His intraocular pressure was 4 mmHg OD and 10 mmHg OS. Anterior segment examination of right eye showed descemet folds, 3+ cells and flare (Figure 1). The right posterior segment examination revealed intense vitritis with snow balls and normal retina (Figure 2). The left eye was unremarkable.

Figure 1. Spillover anterior uveitis

Figure 2. Dense vitritis

Rifabutin associated uveitis was suspected and his medication was switched from rifabutin to levofloxacin. The patient was started on topical prednisolone acetate 1% every hour and phenylephrine 5%-tropicamide 0,5% every 8 hours.

One week later, his visual acuity improved to 20/100 OD, IOP was 9 mmHg, and there was a remarkable reduction in both anterior and posterior segment inflammation. Topical corticosteroids were indicated every 2 hours and dilating drops discontinued. The next week visual acuity of right eye was 20/50, IOP unchanged, anterior chamber showed +0.5 cells, and fundus examination showed less vitreous haze and vitreous condensation inferiorly with snow balls. (Figure 3). Prednisolone acetate 1% was tapered and discontinued in 15 days.

Figure 3. Improvement of intermediate uveitis after 2 weeks’ discontinuation of Rifabutin

Two months after the beginning of symptoms, his visual acuity was 20/20 OU and the intraocular pressure 8 mmHg in both eyes. Anterior and posterior chamber showed a normal exam. (Figure 4).

Figure 4. Normal fundus 2 months later after beginning of intermediate uveitis

3. Discussion

The most distinctive presentation of rifabutin-associated uveitis is an anterior uveitis with or without hypopyon [1,2,3,4], There are some reported cases however of intermediate uveitis, although this is a relatively infrequent manifestation [6,7,8]. Our patient presented with unilateral uveitis which showed a more severe inflammation in the vitreous than in the anterior chamber.

A characteristic of therapy with rifabutin is the dose related toxicity. The dose range of rifabutin associated with uveitis goes between 300 and 1800 mg daily [5,9]. Shafran and colleagues demonstrated that patients on 300 mg/day of rifabutin rarely developed uveitis, and when it occurred, it took at least 7 months of medication use for the uveitis to develop [3]. Skinner and Blaschke later confirmed that drug related uveitis was unusual at the recommended dose of 300 mg/day [9]. Our patient was on 150 mg daily of rifabutin for 4 months before he developed uveitis but he was also taking ritonavir 100 mg/d and fluconazole 200 mg/week. Both drugs interact in the metabolism of rifabutin through inhibition of hepatic cytochrome P450 and may increase the risk of rifabutin-associated uveitis.

Although fluconazole inhibit cytochrome P-450 and increases serum availability of rifabutin [10,11], the association with higher risk of rifabutin induced uveitis is controversial. Shafran and associates found no evidence that concomitant therapy with fluconazole can increase the incidence of uveitis [3]. On the other hand, Havlir et al reported 4 cases of uveitis in patients receiving rifabutin 300 mg daily in combination with fluconazole 400 mg/week that developed uveitis after 7 months of therapy [12].

Ritonavir is a potent inhibitor of CYP3A and has been demonstrated that it can exacerbate the adverse reactions of rifabutin [13,14]. Subsequently, recent guidelines have proposed the use of intermittently administered rifabutin 150 mg 3 times per week or 150 mg daily with close monitoring of adverse effects when used in the combination with ritonavir. Investigators found that the serum concentration of rifabutin, when given at dosages of 150 mg every 3 days in combination with ritonavir, were comparable to concentrations achieved with rifabutin 300 mg once daily in patients not being treated with protease inhibitors [15].

There is only one reported case in the literature of an HIV+ cachectic patient with 150 mg/day of rifabutin combined with triple therapy for HIV causing panuveitis and retinal vasculitis after 6 months of treatment [5]. Low body weight is another known risk factor for the development of rifabutin-induced uveitis [3].

We present a well-documented report of an HIV+ non-cachectic patient with unilateral rifabutin induced intermediate uveitis after 4 months of treatment with a low dose of rifabutin (150 mg qd) in combination with ritonavir and fluconazole. The uveitis resolved in 2 months with discontinuation of rifabutin and the use of intensive topical corticosteroids [1,2,4].

4. Conclusion

Rifabutin is a well-recognized cause of drug induced intraocular inflammation. Patients receiving rifabutin, even in low doses, with combinations of protease inhibitors and/or azoles should be warned about signs and symptoms of uveitis and be monitored closely for the development of rifabutin toxicity.

Conflict of Interest

No conflicting relationship exists for any author.

References

[1]  
B. R. Saran, A. M. Maguire, C. Nichols, I. Frank, R. W. Hertle, A. J. Brucker, S. Goldman, M. Brown, and B. Van Uitert, “Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin,” Arch Ophthalmol, vol. 112, no. 9, pp. 1159-65, Sep, 1994.

[2]   | M. O. Frank, M. B. Graham, and B. Wispelway, “Rifabutin and uveitis,” N Engl J Med, vol. 330, no. 12, pp. 868, Mar 24, 1994.

[3]  
S. D. Shafran, J. Singer, D. P. Zarowny, J. Deschenes, P. Phillips, F. Turgeon, F. Y. Aoki, E. Toma, M. Miller, R. Duperval, C. Lemieux, and W. F. Schlech, 3rd, “Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group,” J Infect Dis, vol. 177, no. 1, pp. 252-5, Jan, 1998.

[4]   | D. S. Jacobs, P. J. Piliero, M. G. Kuperwaser, J. A. Smith, S. D. Harris, T. P. Flanigan, J. H. Goldberg, and D. V. Ives, “Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection,” Am J Ophthalmol, vol. 118, no. 6, pp. 716-22, Dec 15, 1994.
[5]   | S. Skolik, F. Willermain, and L. E. Caspers, “Rifabutin-associated panuveitis with retinal vasculitis in pulmonary tuberculosis,” Ocul Immunol Inflamm, vol. 13, no. 6, pp. 483-5, Dec, 2005.
[6]   | L. Akduman, L. V. Del Priore, H. J. Kaplan, and W. G. Powderly, “Rifabutin induced vitritis in AIDS patients,” Ocul Immunol Inflamm, vol. 4, no. 4, pp. 219-24, 1996.
[7]   | M. J. Chaknis, S. E. Brooks, K. T. Mitchell, and D. M. Marcus, “Inflammatory opacities of the vitreous in rifabutin-associated uveitis,” Am J Ophthalmol, vol. 122, no. 4, pp. 580-2, Oct, 1996.
[8]   | C. Pochat-Cotilloux, F. De Bats, A. M. Nguyen, F. Benbouzid, A. Malcles, P. Denis, and L. Kodjikian, “[Rifabutin-associated bilateral uveitis: a case report],” J Fr Ophtalmol, vol. 37, no. 8, pp. e115-7, Oct, 2014.
[9]   | M. H. Skinner, and T. F. Blaschke, “Clinical pharmacokinetics of rifabutin,” Clin Pharmacokinet, vol. 28, no. 2, pp. 115-25, Feb, 1995.
[10]   | P. K. Narang, C. B. Trapnell, J. R. Schoenfelder, J. P. Lavelle, and J. R. Bianchine, “Fluconazole and enhanced effect of rifabutin prophylaxis,” N Engl J Med, vol. 330, no. 18, pp. 1316-7, May 05, 1994.
[11]   | C. B. Trapnell, P. K. Narang, R. Li, and J. P. Lavelle, “Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients,” Ann Intern Med, vol. 124, no. 6, pp. 573-6, Mar 15, 1996.
[12]   | D. Havlir, F. Torriani, and M. Dube, “Uveitis associated with rifabutin prophylaxis,” Ann Intern Med, vol. 121, no. 7, pp. 510-2, Oct 01, 1994.
[13]   | A. Cato, 3rd, J. Cavanaugh, H. Shi, A. Hsu, J. Leonard, and R. Granneman, “The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin,” Clin Pharmacol Ther, vol. 63, no. 4, pp. 414-21, Apr, 1998.
[14]   | H. C. Lin, P. L. Lu, and C. H. Chang, “Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra),” Eye (Lond), 12, pp. 1540-1, England, 2007.
[15]   | J. I. Kuper, and M. D'Aprile, “Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease,” Clin Pharmacokinet, vol. 39, no. 3, pp. 203-14, Sep, 2000.